Cover Image
市場調查報告書

鹼性磷酸酶 (ALKP):開發平台分析

Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 359841
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
鹼性磷酸酶 (ALKP):開發平台分析 Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1) - Pipeline Review, H2 2016
出版日期: 2016年09月30日 內容資訊: 英文 60 Pages
簡介

本報告提供以鹼性磷酸酶為標的的藥物之適應症,開發階段,作用機制,給藥途徑及各分子類型分析,提供您藥物的藥理作用相關記述,迄今的研究開發趨勢,最新的新聞和發表,藥物的主要開發企業概要,休止/中止的計劃等資訊。

簡介

  • 調查範圍

鹼性磷酸酶概要

治療藥的開發

鹼性磷酸酶:開發中的產品 - 各開發階段

鹼性磷酸酶:開發中的產品 - 各治療範圍

鹼性磷酸酶:開發中的產品 - 各適應症

鹼性磷酸酶:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

鹼性磷酸酶:企業開發中的產品

鹼性磷酸酶:大學/機關開發中的產品

鹼性磷酸酶:治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

鹼性磷酸酶的治療藥開發企業

  • Alexion Pharmaceuticals, Inc.
  • Am-Pharma B.V.
  • Cilian AG
  • Synthetic Biologics, Inc.

藥物簡介

鹼性磷酸酶:暫停中的計劃

鹼性磷酸酶:主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0559TDB

Summary

Global Markets Direct's, 'Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1) - Pipeline Review, H2 2016', provides in depth analysis on Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1)
  • The report reviews Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1) Overview
  • Therapeutics Development
    • Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1) - Products under Development by Stage of Development
    • Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1) - Products under Development by Therapy Area
    • Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1) - Products under Development by Indication
  • Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1) - Products under Development by Companies
  • Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1) - Products under Development by Universities/Institutes
  • Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1) - Companies Involved in Therapeutics Development
    • Alexion Pharmaceuticals Inc
    • Am-Pharma B.V.
    • Cilian AG
    • Synthetic Biologics, Inc.
  • Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1) - Drug Profiles
    • asfotase alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Alkaline Phosphatase Replacement for Sepsis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Human Alkaline Phosphatase Replacement for Acute Renal Failure, Hypophosphatasia, Sepsis and Ulcerative Colitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SBI-425 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SYN-020 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1) - Dormant Projects
  • Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1) - Featured News & Press Releases
    • Sep 22, 2016: Alexion statement: NICE 2nd ECD for Strensiq (asfotase alfa)
    • May 10, 2016: AM-Pharma publishes safety and pharmacokinetic data from Phase I recAP trial
    • Apr 26, 2016: AM-Pharma receives FDA fast track designation for recAP in Acute Kidney Injury
    • Apr 04, 2016: Data Presented at ENDO 2016 Show Sustained Improvements in Survival Rates, Bone Healing, Respiratory Support and Physical Function in Children with Hypophosphatasia (HPP) Receiving Long-Term Treatment with Strensiq (asfotase alfa)
    • Jan 15, 2016: Researchers to Present New Data at ENDO 2016 Advancing the Understanding of Strensiq (asfotase alfa) in Infants, Children and Adult Patients with Hypophosphatasia (HPP)
    • Dec 03, 2015: Benefits of new drug to treat rare inherited bone disorder too uncertain to justify its high cost says NICE in draft guidance
    • Oct 23, 2015: FDA Approves Strensiq (asfotase alfa) for Treatment of Patients with Perinatal-, Infantile- and Juvenile-Onset Hypophosphatasia
    • Oct 12, 2015: Significant Improvements in Skeletal Mineralization and Physical Function Observed in Children with Hypophosphatasia Treated With Strensiq (asfotase alfa) Sustained for at least Five Years
    • Sep 16, 2015: Alexion Announces Presentations at 2015 American Society for Bone and Mineral Research Annual Meeting, Including New Data on Strensiq in Children with Hypophosphatasia Treated for Five Years
    • Sep 01, 2015: European Commission Grants Marketing Authorization for Strensiq for the Treatment of Patients with Pediatric-Onset Hypophosphatasia
    • Aug 17, 2015: Health Canada Approves Strensiq (asfotase alfa), the First Therapy for Patients with Hypophosphatasia (HPP), an Ultra-rare, Life-threatening Disease
    • Jul 06, 2015: Strensiq Receives Marketing Approval in Japan for Treatment of Patients with Hypophosphatasia
    • Jun 26, 2015: Alexion Receives CHMP Positive Opinions for Strensiq in the European Union
    • Jun 09, 2015: AM-Pharma receives FDA and EMA orphan drug designation to treat hypophosphatasia
    • Mar 07, 2015: New Data from First Natural History Study in Juveniles with Hypophosphatasia Showing Substantial Disease Burden, Including Musculoskeletal Abnormalities and Growth Deficiencies, Presented in Late-Breaking Oral Session at ENDO 2015
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Alexion Pharmaceuticals Inc, H2 2016
  • Pipeline by Am-Pharma B.V., H2 2016
  • Pipeline by Cilian AG, H2 2016
  • Pipeline by Synthetic Biologics, Inc., H2 2016
  • Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top